More Company News

Hutchison China MediTech

Global collaboration with Innovent expanded to include surufatinib
10 Oct 2019Read More

Hutchison China MediTech

Initiation of international Phase I/Ib trial of HMPL-523 in advanced relapsed or refractory lymphoma
04 Oct 2019Read More

Hutchison China MediTech

CK Hutchison prices Chi-Med share offering enabling deconsolidation & confirms intent to hold Chi-Med as a long-term strategic investment
30 Sep 2019Read More

Hutchison China MediTech

Chi-Med to discuss surufatinib Phase III and US Phase I/Ib efficacy and safety data presented at ESMO
29 Sep 2019Read More

Hutchison China MediTech

Presentation of clinical data from the successful Phase III SANET-ep trial at ESMO
25 Sep 2019Read More

Hutchison China MediTech

Oral Presentations at 2019 CSCO Annual Meeting
18 Sep 2019Read More

Hutchison China MediTech

Initiation of China Phase I trial of HMPL-523 in Immune Thrombocytopenia (ITP)
23 Aug 2019Read More

Hutchison China MediTech

2019 Interim Results and Clinical Update
30 Jul 2019Read More

Hutchison China MediTech

Chi-Med to announce H119 financial results
03 Jul 2019Read More

Hutchison China MediTech

Pricing of upsized US Public Secondary Offering of ADS
28 Jun 2019Read More

1 2 3
Return to Hutchison China MediTech
© 2019 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).